Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : RNAi -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (87)	9/10/2003 1:43:24 PM
From: tuck	Respond to of 671

Meanwhile, if the recent licensing activity seemed to be clearing the IP murk, this patent application might start clouding it again: appft1.uspto.gov It concerns systemic RNAi, particularly a protein that seems to be required for it: >>Science. 2002 Mar 29;295(5564):2456-9. Epub 2002 Feb 07. Systemic RNAi in C. elegans requires the putative transmembrane protein SID-1. Winston WM, Molodowitch C, Hunter CP. Department of Molecular and Cellular Biology, Harvard University, 16 Divinity Avenue, Cambridge, MA 02138, USA. Double-stranded RNA-mediated gene interference (RNAi) in Caenorhabditis elegans systemically inhibits gene expression throughout the organism. To investigate how gene-specific silencing information is transmitted between cells, we constructed a strain that permits visualization of systemic RNAi. We used this strain to identify systemic RNA interference-deficient (sid) loci required to spread gene-silencing information between tissues but not to initiate or maintain an RNAi response. One of these loci, sid-1, encodes a conserved protein with predicted transmembrane domains. SID-1 is expressed in cells sensitive to RNAi, is localized to the cell periphery, and is required cell-autonomously for systemic RNAi.<< Cheers, Tuck